In Brief: Abbott
Executive Summary
Abbott: Expanded access program for protease inhibitor ritonavir will be managed by the Philadelphia-based CRO Medex. Abbott will be making ritonavir available to about 2,000 patients worldwide via a lottery set to begin in mid-January. AIDS patients with CD4 counts below 50 cells/mm3 who are over the age of 12 will be eligible for the lottery, with further information available at 1-800-414-AIDS...